AMA submission to the Review of anticoagulation therapies in atrial fibrillation
The AMA has made comments on a Government review of anticoagulation therapies for patients with atrial fibrillation (AF). The AMA continues to call for adequate Medicare rebates that reflect the longer consultations required for patients with AF, as well as the introduction of a rebate to assist patients to access INR point-of-care testing. The lack of a Medicare rebate poses a barrier to the wider take-up of this service. The AMA also emphasised that the management of patients with AF must be closely supervised by a medical practitioner, given it is common for patients with AF to have a wide range of co-morbidities.
The AMA has made comments on a Government review of anticoagulation therapies for patients with atrial fibrillation (AF).
The AMA continues to call for adequate Medicare rebates that reflect the longer consultations required for patients with AF, as well as the introduction of a rebate to assist patients to access INR point-of-care testing. The lack of a Medicare rebate poses a barrier to the wider take-up of this service. The AMA also emphasised that the management of patients with AF must be closely supervised by a medical practitioner, given it is common for patients with AF to have a wide range of co-morbidities.
Read the AMA comments in full here.
